Now PlayingEP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
Future Directions and Unmet Needs in HER2+ Breast Cancer TherapyByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOPFebruary 4th 2026
Additional Emerging HER2-Targeted Therapies in NSCLCByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhDFebruary 4th 2026
Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLCByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhDFebruary 4th 2026
Addressing Care Coordination and Financial Toxicity in HER2+ Breast CancerByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOPFebruary 4th 2026
Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple MyelomaByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOPFebruary 3rd 2026